Evidence map›Paper›PMID 39489762›Full record

ArticleNPJ primary care respiratory medicine2024

Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population.

Ming Ren Toh, Gerald Xuan Zhong Ng, Ishita Goel, Shao Wei Lam, Jun Tian Wu, Chun Fan Lee, Marcus Eng Hock Ong, David Bruce Matchar, Ngiap Chuan Tan, Chian Min Loo and 1 more

Abstract read
In one paragraph

Article in NPJ primary care respiratory medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Guideline-based asthma treatment in Asia: Insights from a robust time-in-state model.The journal of allergy and clinical immunology. Global · 2025
    Article
  5. Article
  6. Environmental sustainability in asthma: reducing carbon footprint and medication wastage.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
  7. Optimizing adherence to medication to improve outcomes in asthma.Current opinion in pulmonary medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ming Ren TohDuke-NUS Medical School, Singapore, Singapore. mingren.toh@mohh.com.sg.
Gerald Xuan Zhong NgDuke-NUS Medical School, Singapore, Singapore.
Ishita GoelSchool of physical and mathematical sciences, Nanyang Technological University, Singapore, Singapore.
Shao Wei LamHealth Services Research, Duke-NUS Medical School, Singapore, Singapore.
Jun Tian WuHealth Services Research, Duke-NUS Medical School, Singapore, Singapore.
Chun Fan LeeDuke-NUS Medical School, Singapore, Singapore.
Marcus Eng Hock OngDuke-NUS Medical School, Singapore, Singapore.
David Bruce MatcharDuke-NUS Medical School, Singapore, Singapore.
Ngiap Chuan TanSingHealth Polyclinics, Singapore, Singapore.
Chian Min LooDuke-NUS Medical School, Singapore, Singapore.
Mariko Siyue KohDuke-NUS Medical School, Singapore, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhaled corticosteroid (ICS) is the mainstay therapy for asthma, but general adherence is low. There is a paucity of real-world inhaler prescribing and adherence data from Asia and at the population level. To address these gaps, we performed a real-world data analysis of inhaler prescribing pattern and adherence in a multi-ethnic Asian asthma cohort and evaluated the association with asthma outcomes. We performed a retrospective analysis of adult asthma patients (aged ≥18 years) treated in the primary and specialist care settings in Singapore between 2015 to 2019. Medication adherence was measured using the medication possession ratio (MPR), and categorised into good adherence (MPR 0.75-1.2), poor adherence (MPR 0.75) or medication oversupply (MPR > 1.2). All statistical analyses were performed using R Studio. 8023 patients, mean age 57 years, were evaluated between 2015 and 2019. Most patients were receiving primary care (70.4%) and on GINA step 1-3 therapies (78.2%). ICS-long-acting beta-2 agonist (ICS-LABA) users increased over the years especially in the primary care, from 33% to 52%. Correspondingly, inpatient admission and ED visit rates decreased over the years. Between 2015 and 2019, the proportion of patients with poor adherence decreased from 12.8% to 10.5% (for ICS) and from 30.0% to 26.8% (for ICS-LABA) respectively. Factors associated with poor adherence included minority ethnic groups (Odds ratio of MPR 0.75-1.2: 0.73-0.93; compared to Chinese), presence of COPD (OR 0.75, 95% CI 0.59-0.96) and GINA step 4 treatment ladder (OR 0.71, 95% CI 0.61-0.85). Factors associated with good adherence were male gender (OR 1.14, 95% CI 1.01-1.28), single site of care (OR 1.22 for primary care and OR 1.76 for specialist care), GINA step 2 treatment ladder (OR 1.28, 95% CI 1.08-1.50). Good adherence was also associated with less frequent inpatient admission (OR 0.91, 95% CI 0.84-0.98), greater SABA overdispensing (OR 1.66, 95% CI 1.47-1.87) and oral corticosteroids use (OR 1.10, 95% CI 1.05-1.14). Inhaled corticosteroid (ICS) adherence has improved generally, however, poor adherence was observed for patients receiving asthma care in both primary and specialist care, and those from the minority ethnicities.

Indexed as

AsthmaDrug MonitoringAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAdultAgedAnti-Asthmatic AgentsAsian PeopleFemaleHumansMaleMiddle AgedNebulizers and VaporizersPractice Patterns, Physicians'Retrospective StudiesAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAnti-Asthmatic Agents

Identifiers

PMID39489762
PMCPMC11532544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.